Calcium channel blocking agents in the treatment of cardiovascular disorders. Part II: Hemodynamic effects and clinical applications.
about
An exercise hemodynamic comparison of verapamil, diltiazem, and amlodipine in coronary artery diseaseThe effect of flunarizine on erythrocyte suspension viscosity under conditions of extreme hypoxia, low pH, and lactate treatment.A randomised double-blind trial of diltiazem in the treatment of Raynaud's phenomenonPurification and affinity labeling of dihydropyridine receptor from rabbit skeletal muscle membranes.Principal component analysis of HPLC retention data and molecular modeling structural parameters of cardiovascular system drugs in view of their pharmacological activity.Alpha adrenergic-mediated accumulation of calcium in reperfused myocardium.Influence of nicardipine on the pharmacokinetics and pharmacodynamics of propranolol in healthy volunteersPharmacokinetics and pharmacodynamics of nifedipine infusion in normal volunteers.Nicardipine for stable angina pectorisHaemodynamic dose-response effects of intravenous nisoldipine in coronary artery diseaseEffects of verapamil and alcohol on blood flow, melphalan uptake and cytotoxicity, in murine fibrosarcomas and human melanoma xenografts.Method development and validation study for quantitative determination of nifedipine and related substances by ultra-high-performance liquid chromatography.Rebound of vasospastic angina after cessation of long-term treatment with nifedipineImportance of myocardial blood flow changes in the protective action of diltiazem in a new model of myocardial ischaemia[3H]nitrendipine-labeled calcium channels discriminate inorganic calcium agonists and antagonists.Nifedipine in primary Raynaud's phenomenon and in scleroderma: oral versus sublingual hemodynamic effects.A comparison of diltiazem and atenolol in angina.Cardiac rhythm in hypertension assessed through 24 hour ambulatory electrocardiographic monitoring. Effects of load manipulation with atenolol, verapamil, and nifedipine.The calcium-channel blocker controversy: historical perspective and important lessons for future pharmacotherapies. An international society of pharmacoepidemiology 'hot topic'.Dihydropyridine receptor in rat brain labeled with [3H]nimodipine.Rationale for treatment of silent myocardial ischemia: focus on nifedipine.Calcium and pH in anoxic and toxic injury.Classification of antiarrhythmic drugs.Nifedipine as a therapeutic modality for Raynaud's phenomenon.Does coronary artery bypass grafting improve survival?Infarct size reduction: a review of the clinical trials.Observations on the warm up phenomenon in angina pectoris.Coronary vasomotor and clinical effects of nifedipine in effort, mixed and Prinzmental angina.Studies on verapamil in the treatment of essential hypertension: a review.Clinical digoxin toxicity in the aged in association with co-administered verapamil. A report of two cases and review of the literature.Diltiazem.The hemodynamic effects of calcium channel blocking agents: a brief review.Mechanisms of action of membrane calcium channel blockers and intracellular calcium antagonists.Calcium entry blockers: a review.Verapamil: full spectrum calcium channel blocking agent: an overview.Vasodilators.Pharmacological basis for the therapeutic applications of slow-channel blocking drugs.Binding of a calcium antagonist, [3H]nitrendipine, to high affinity sites in bovine aortic smooth muscle and canine cardiac membranes.Subgingival microflora associated with nifedipine-induced gingival overgrowth.Acute haemodynamic and metabolic effects of felodipine in congestive heart failure
P2860
Q28330167-49CEE6C5-F547-40B6-9D07-BFF5CE2E28ECQ30486869-16F96C1E-BF59-4406-BA28-A88EDBF6B02EQ33555611-3A4AB870-4709-4839-AF38-942FEC598D88Q33569630-56DAE2B1-D6C4-4F64-B148-CBDA8BC41E90Q33662066-EDC42A97-E9AB-4EF6-B297-DAB531BB8473Q33822207-1E1B3669-AEC3-4457-A67E-DFF5F6A1D9F5Q34398398-B4CCE30C-F2D9-4366-BBC3-1D42E1553E93Q34416554-38C04EA4-6ADB-418A-B3B5-B78A084D92FCQ34446965-E979C860-F32C-423A-9593-871A46E120DEQ34447068-2B407A1A-02BA-425F-8D4F-4CC97223ECA4Q34691861-8279DF91-A877-4C84-8D5C-EF34663EC8B8Q35201251-2FDAAB66-B8B3-4694-A9A9-C0E80789C792Q35807489-F505E95F-688A-4D2D-A072-CA05B55DD2A5Q35886648-59614563-DE43-4C0D-8023-8A2278DB8606Q36299246-222E31BE-3A63-4E0B-852F-A92A5FFCF96CQ36456403-B511BAC0-8820-47A1-9753-7E9A6C3ED744Q36706576-F1EE53D3-0E40-45E8-99B6-4888D743CF52Q36745405-A75F7645-CA6A-463C-B7F8-886BBF32F61EQ37331867-1776C559-90A9-4B90-A993-199F983FEBC0Q37609501-B05A8E07-3E98-46A2-A2DE-7063B10B0745Q37782866-7086C264-52D6-4D1E-8D8F-C53877093A77Q37787068-C7B05E9D-951A-4130-8465-11BBFAEEC46DQ38651993-85E1ECFC-E7BE-4BB0-8EF6-E99D044CD25AQ39349281-71CA8E6C-9F0A-414C-9E4E-0B7E907DFFEAQ39387527-BA1B6306-40EE-4BDC-AE6A-84913577ACCCQ39436280-5F54FF47-209B-42EC-951E-6E1BD834E520Q39510782-52045806-9A71-478C-97A3-8BDD213DBE1CQ39534523-3A02E111-38D5-4396-B627-F9B191BA2997Q39743021-4AD9CBCD-0397-435F-97FC-7B5B2E6BCBADQ39792360-4CA471E6-2AA3-484E-8167-0FD632C0DA42Q39814577-A1C8C54A-D18E-4017-B1FD-F4B311E5419DQ40130871-C8F568BE-7F4A-43D0-A230-27CA6B501AE2Q40134576-C22C7E1E-14F7-42B9-B84B-F8765C230228Q40135660-7BDB0340-9A71-469F-9AB5-8D45400159F1Q40139956-3B6B0ED6-2A3E-47DB-9BBB-408050E77C78Q40155306-56988360-2692-4941-AAA3-25DC1D0921D7Q40338219-06434133-63CE-414C-B92A-EEF8A9AFFF78Q40681368-66DACBFA-C1E7-4707-B559-CE297B50796CQ40851801-66710498-EA9D-4E5C-95EE-B9255156B343Q41305795-47BF66FB-59C9-4486-8BAF-0AE692D4AF5B
P2860
Calcium channel blocking agents in the treatment of cardiovascular disorders. Part II: Hemodynamic effects and clinical applications.
description
1980 nî lūn-bûn
@nan
1980年の論文
@ja
1980年論文
@yue
1980年論文
@zh-hant
1980年論文
@zh-hk
1980年論文
@zh-mo
1980年論文
@zh-tw
1980年论文
@wuu
1980年论文
@zh
1980年论文
@zh-cn
name
Calcium channel blocking agent ...... cts and clinical applications.
@en
type
label
Calcium channel blocking agent ...... cts and clinical applications.
@en
prefLabel
Calcium channel blocking agent ...... cts and clinical applications.
@en
P2093
P1476
Calcium channel blocking agent ...... cts and clinical applications.
@en
P2093
P304
P356
10.7326/0003-4819-93-6-886
P407
P577
1980-12-01T00:00:00Z